EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, KPTI: Karyopharm Therapeut

26 Aug 26 08:36
LAST:

1.940

CHANGE:
 0.03		OPEN:
1.960		HIGH:
1.960		ASK:
13.080		VOLUME:
1.9K
CHG(%):
1.57		PREV:
1.910		LOW:
1.940		BID:
8.510		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Aug 261.9601.9601.9401.9401.9K
25 Aug 261.8701.9501.8701.9201.06M
24 Aug 261.9501.9601.8301.860845.7K
21 Aug 261.8501.9701.8221.960876.7K
20 Aug 262.0002.0001.8201.820865.6K
19 Aug 261.9302.0151.9302.000792.1K
18 Aug 261.8801.9601.8201.9301.15M
17 Aug 262.0202.0301.7901.8101.39M
14 Aug 261.9702.0601.9702.020886.9K
13 Aug 262.0302.0871.9201.9901.73M

PROFILE

Name:Karyopharm Therapeut
About:Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:85 Wells Avenue, Newton, MA, United States, 02459-3298
Website:https://www.karyopharm.com
CUSIP:48576U106
CIK:0001503802
ISIN:US48576U2050
FIGI:BBG001J272L7

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.64 
Forward P/E:-1.96 
PEG Ratio:0.00 
Price to Sales:0.67 
Price to Book:-0.81 
Profit Margin:-0.90 
Operating Margin:-0.64 
Return on Assets:-0.45 
Return on Equity:0.41 
EPS Ratio:-16.40 
Revenue:137.27M 
Shares:22.66M 
Market Cap:43.97M 

TECHNICAL INDICATORS

MA5:1.901.9%
MA10:1.930.7%
MA20:2.2113.9%
MA50:6.31225.3%
MA100:7.47285.0%
MA200:7.27274.5%
STO9:60.00
STO14:40.54
RSI14:50.33
WPR14:-51.61
MTM14:-0.16
ROC14:-0.08 
ATR:0.16 
Week High:2.023.9%
Week Low:1.826.6%
Month High:7.84304.1%
Month Low:1.79274.5%
Year High:10.99466.5%
Year Low:1.798.4%
Volatility:20.00 

RECENT SPLITS

Date Ratio
26 Feb 20251-15